Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Swarup Gupta headshot

6 Stocks to Prepare for a Global Economic Slowdown

A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.

J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft

J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.

Company News For Jan 22, 2019

Companies In The News Are: TIF,LLY,KSU,JBHT

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

Here is Why Growth Investors Should Buy Lilly (LLY) Now

Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.

Madhu Goel headshot

Pacira's Study on Exparel Label Expansion Meets Endpoints

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

Ligand (LGND) Takes a Hit on Citron's Negative Research Report

Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.

Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

Intrexon Signs Licensing Agreement with Next Green Wave

Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

Eli Lilly (LLY) closed at $114.68 in the latest trading session, marking a -1.29% move from the prior day.

5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

Kinjel Shah headshot

4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting

Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

Novartis' Crizanlizumab Gets Breakthrough Therapy Status

Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.

Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo

Lilly (LLY) looks to acquire small cancer biotech, Loxo Oncology, to expand its pipeline into targeted cancer therapies.

Crowded Cancer Space Triggers Big M&A Deals: More in Store?

Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.

Company News For Jan 8, 2019

Companies In The News Are: LOXO,LLY,DLTR,PCG,MAT

Ekta Bagri headshot

4 Biotechs That Are Potential Buyouts Post Celgene Deal

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.